Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 5, 2003, Pages 859-863

  Ridker, Paul M ^a   Cook, Nancy R ^a   Cheng, Suzanne ^b   Erlich, Henry A ^b   Lindpaintner, Klaus ^c   Plutzky, Jorge ^a   Zee, Robert Y L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Epidemiology; Genetics; Myocardial infarction; Polymorphism; Risk prediction

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE; GENE TARGETING; GENE THERAPY; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PPARG2 GENE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; CODON; COHORT STUDIES; DIABETES MELLITUS; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNITY, NATURAL; INCIDENCE; MALE; MIDDLE AGED; MODELS, GENETIC; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK; TRANSCRIPTION FACTORS; UNITED STATES;

EID: 0037625000     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000068680.19521.34     Document Type: Article

References (19)

1. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A pro12ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-287.
2. 12ala polymorphism in PPARγ may confer resistance to type 2 diabetes. Biochem Biophys Res Commun. 2000;271:212-216.
3. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARγ pro12ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genetics. 2000;26:76-80.
4. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M. The pro12ala substitution in PPARγ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001;50:891-894.
5. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep. 2000;2:327-335.
6. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823-834.
7. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
8. Cheng S, Pallaud C, Grow MA, Scharf SJ, Erlich HA, Klitz W, Pullinger CR, Malloy MJ, Kane JP, Siest G, Visvikis S. A multilocus genotyping assay for cardiovascular disease. Clin Chem Lab Med. 1998;36:561-566.
9. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, Kane JP. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res. 1999;9:936-949.
10. Tontonoz P, Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. Curr Opin Lipidol. 1999;10:485-490.
11. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
12. O'Rahilly S. Insights into obesity and insulin resistance from the study of extreme human phenotypes. Eur J Endocrinol. 2002;147:435-441.
13. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab. 2002;87:408-411.
14. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 2002;51:3586-3590.
15. Pradhan A, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J. 2002;23:831-834.
16. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor γ C161→T polymorphism and coronary artery disease. Cardiovas Res. 1998;44:588-594.
17. Ridker PM, Stampfer MJ. Assessment of genetic markers for coronary thrombosis: promise and precaution. Lancet. 1999;353:687-688.
18. Pasceri V, Wu HD, Willerson JT, Yeh ETH. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation. 2000;101:235-238.
19. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000;268:178-182.